Inicio › Cáncer de ovario › Ohio

Ensayos clínicos de Cáncer de ovario en Ohio

68 estudios sobre Cáncer de ovario buscan participantes en Ohio.

Ciudades en Ohio

Texto oficial del estudio (inglés)

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

Ohio State University Comprehensive Cancer Center, Columbus

ReclutandoFase 2/3

Edades de 18 en adelante · Todos los sexos · Actualizado el 13 nov 2026 · NCT07001748

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

OhioHealth O'Bleness Hospital, Athens
UH Seidman Cancer Center at UH Avon Health Center, Avon
UHHS-Chagrin Highlands Medical Center, Beachwood
y 41 más

ReclutandoFase 2

Todas las edades · Todos los sexos · Actualizado el 12 nov 2026 · NCT05564377

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

University of Cincinnati Medical Center ( Site 0090), Cincinnati
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0054), Columbus

ReclutandoFase 3

Edades de 18 en adelante · Mujeres · Actualizado el 10 nov 2026 · NCT06824467

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

University of Cincinnati Medical Center ( Site 0042), Cincinnati
The Ohio State University ( Site 0005), Hilliard

ReclutandoFase 3

Edades de 18 en adelante · Mujeres · Actualizado el 10 nov 2026 · NCT07318558

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

OhioHealth O'Bleness Hospital, Athens
UHHS-Chagrin Highlands Medical Center, Beachwood
Geauga Hospital, Chardon
y 26 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 9 nov 2026 · NCT06580314

A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

Site 0108, Columbus

ReclutandoFase 3

Edades de 18 en adelante · Mujeres · Actualizado el 9 nov 2026 · NCT07546500

Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer

Research Site, Cleveland

ReclutandoFase 3

Edades de 18 en adelante · Mujeres · Actualizado el 6 nov 2026 · NCT07851025

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

The Ohio State University Comprehensive Cancer Center, Hilliard

ReclutandoFase 2

Edades de 18 en adelante · Mujeres · Actualizado el 6 nov 2026 · NCT06787612

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

Aultman Alliance Community Hospital, Alliance
OhioHealth O'Bleness Hospital, Athens
UHHS-Chagrin Highlands Medical Center, Beachwood
y 37 más

Reclutando

Edades de 35 a 50 · Mujeres · Actualizado el 6 nov 2026 · NCT04251052

The Vanguard Study: Testing a New Way to Screen for Cancer

Louis Stokes Cleveland VA Medical Center, Cleveland

ReclutandoSe aceptan voluntarios sanos

Edades de 45 a 75 · Todos los sexos · Actualizado el 6 nov 2026 · NCT06995898

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

Cleveland Clinic Foundation, Cleveland

ReclutandoEstudio observacional

Edades de 18 en adelante · Mujeres · Actualizado el 5 nov 2026 · NCT05051722

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

University Hospitals Cleveland Medical Center, Cleveland

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06465069

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

Miami Valley Hospital South, Centerville
University of Cincinnati Medical Center, Cincinnati
Oncology Hematology Care Inc, Cincinnati
y 7 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT07213804

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute, Columbus

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT05579366

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

The Ohio State University (OSU) Wexner Medical Center, Columbus

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06400472

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Cleveland Clinic - Oncology Department, Cleveland

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06760819

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

The Christ Hospital Physicians - Mt. Auburn, Cincinnati
Ohio State University CRS, Columbus

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT06303505

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Site 0147 - Trihealth Cancer Institute - Harold and Eugen, Cincinnati
Site 0243 - Mark H Zangmeister Cancer Center, Columbus
Site 0214-Ohio State University Comprehensive Cancer Center, Hilliard

ReclutandoFase 2

Edades de 18 en adelante · Mujeres · Actualizado el 30 oct 2026 · NCT05128825

Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring

Cleveland Clinic Mercy Hospital, Canton
University Hospitals Seidman Cancer Center, Cleveland
Tri-County Hematology & Oncology Associates, Inc., Massillon

ReclutandoEstudio observacional

Edades de 18 en adelante · Todos los sexos · Actualizado el 30 oct 2026 · NCT05974150

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

Cleveland Clinic Taussig Cancer Institute, Cleveland

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 29 oct 2026 · NCT06774963

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

UH Cleveland Medical Center, Cleveland

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 28 oct 2026 · NCT07109726

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

Miami Valley Hospital South, Centerville

ReclutandoFase 3

Edades de 18 en adelante · Mujeres · Actualizado el 28 oct 2026 · NCT06819007

Lead-212 PSV359 Therapy for Patients With Solid Tumors

Cleveland Clinic, Cleveland
Ohio State University, Columbus

ReclutandoFase 1/2

Edades de 18 a 90 · Todos los sexos · Actualizado el 28 oct 2026 · NCT06710756

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Ohio State University Wexner Medical Center, Hilliard

ReclutandoFase 2/3

Edades de 18 en adelante · Todos los sexos · Actualizado el 26 oct 2026 · NCT06161025

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

The Ohio State University Comprehensive Cancer Center, Columbus

ReclutandoEstudio observacional

Edades de 18 en adelante · Todos los sexos · Actualizado el 26 oct 2026 · NCT04981119

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Oncology Hematology Care Primary, Cincinnati
Taylor Cancer Research Center, Maumee

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 22 oct 2026 · NCT04657068

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Metrohealth Medical Center - Cleveland /ID# 276664, Cleveland
Cleveland Clinic - Cleveland /ID# 276133, Cleveland
Cleveland Clinic - Cleveland /ID# 278273, Cleveland
y 3 más

ReclutandoFase 2

Edades de 18 en adelante · Mujeres · Actualizado el 20 oct 2026 · NCT06890338

Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer

Research Site, Cleveland
Research Site, Cleveland
Research Site, Mayfield Heights

ReclutandoFase 3

Edades de 18 en adelante · Mujeres · Actualizado el 16 oct 2026 · NCT07816666

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

Jamescare Gynecologic Oncology At Mill Run /ID# 277951, Hilliard

ReclutandoFase 2

Edades de 18 en adelante · Mujeres · Actualizado el 13 oct 2026 · NCT07059845

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

The Ohio State University, Columbus

ReclutandoFase 1

Edades de 15 en adelante · Todos los sexos · Actualizado el 9 oct 2026 · NCT06276491

Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

Miami Valley Hospital South, Centerville
Zangmeister Cancer Center, Columbus

ReclutandoFase 3

Edades de 18 en adelante · Mujeres · Actualizado el 6 oct 2026 · NCT07225270

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

Research Site, Columbus

ReclutandoFase 1/2

Edades de 18 a 130 · Todos los sexos · Actualizado el 5 oct 2026 · NCT05797168

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Cleveland Clinic Taussig Cancer Center, Cleveland

ReclutandoFase 1/2

Edades de 12 en adelante · Todos los sexos · Actualizado el 2 oct 2026 · NCT04585750

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

University of Cincinnati Medical Center. /ID# 278925, Cincinnati
University Hospitals Cleveland Medical Center /ID# 279601, Cleveland

ReclutandoFase 2

Edades de 18 en adelante · Mujeres · Actualizado el 1 oct 2026 · NCT07024784

A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors

Site 06, Maumee

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT07814248

Study of AVZO-021 in Patients With Advanced Solid Tumors

Avenzo Therapeutics Recruiting Site, Cleveland

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT05867251

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

The Ohio State University Wexner Medical Center, Columbus

ReclutandoFase 1/2

Edades de 18 en adelante · Mujeres · Actualizado el 25 sept 2026 · NCT03564340

DESTINY-PANTUMOUR04

Research Site, Canton
Research Site, Maumee

ReclutandoEstudio observacional

Edades de 18 a 130 · Todos los sexos · Actualizado el 25 sept 2026 · NCT07124000

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

The Ohio State University Wexner Medical Center, Columbus

ReclutandoFase 1/2

Edades de 18 en adelante · Mujeres · Actualizado el 24 sept 2026 · NCT04590326

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Research Site, Cincinnati
Research Site, Columbus

ReclutandoFase 2

Edades de 18 a 130 · Todos los sexos · Actualizado el 23 sept 2026 · NCT05489211

De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.